ORTHO CLINICAL DIAGNOSTICS H (OCDX) Stock Price, Forecast & Analysis
USA - NASDAQ:OCDX - GB00BMDNH979 - Common Stock
OCDX Key Statistics, Chart & Performance
The current stock price of OCDX is 17.63 null. In the past month the price increased by 0.23%. In the past year, price decreased by -14.21%.
OCDX Latest News, Press Relases and Analysis
OCDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 219.11B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.92 | 206.56B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.21 | 149.52B | ||
| SYK | STRYKER CORP | 26.96 | 135.73B | ||
| IDXX | IDEXX LABORATORIES INC | 56.27 | 56.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.6 | 52.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.72 | 49.36B | ||
| RMD | RESMED INC | 25.26 | 36.50B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.01 | 33.55B | ||
| PODD | INSULET CORP | 70.1 | 22.55B | ||
| DXCM | DEXCOM INC | 29.48 | 21.51B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.58B |
Related stock screener links
About OCDX
Company Profile
Ortho Clinical Diagnostics Holdings Plc provides vitro diagnostics services. The company is headquartered in Raritan, New Jersey and currently employs 4,800 full-time employees. The company went IPO on 2021-01-28. The firm provides laboratory testing and blood-typing solutions to the clinical laboratory and transfusion medicine communities. The firm provides customized solutions for clinical outcomes, lab performance and staffing challenges. The firm operates through two lines of business such as Clinical Laboratories and Transfusion Medicine. Its Clinical Laboratories business focuses on clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across therapeutic areas. The Transfusion Medicine business is focused on immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions. Its Donor Screening business is focused on instruments and tests used for blood and plasma screening for infectious diseases for customers, which include some of the donor testing institutions.
Company Info
ORTHO CLINICAL DIAGNOSTICS H
1001 Route 202
Raritan NEW JERSEY 08869 US
CEO: Chris Smith
Employees: 4800
Phone: 19082188000.0
ORTHO CLINICAL DIAGNOSTICS H / OCDX FAQ
Can you describe the business of ORTHO CLINICAL DIAGNOSTICS H?
Ortho Clinical Diagnostics Holdings Plc provides vitro diagnostics services. The company is headquartered in Raritan, New Jersey and currently employs 4,800 full-time employees. The company went IPO on 2021-01-28. The firm provides laboratory testing and blood-typing solutions to the clinical laboratory and transfusion medicine communities. The firm provides customized solutions for clinical outcomes, lab performance and staffing challenges. The firm operates through two lines of business such as Clinical Laboratories and Transfusion Medicine. Its Clinical Laboratories business focuses on clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across therapeutic areas. The Transfusion Medicine business is focused on immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions. Its Donor Screening business is focused on instruments and tests used for blood and plasma screening for infectious diseases for customers, which include some of the donor testing institutions.
What is the current price of OCDX stock?
The current stock price of OCDX is 17.63 null. The price increased by 0.46% in the last trading session.
Does ORTHO CLINICAL DIAGNOSTICS H pay dividends?
OCDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCDX stock?
OCDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about ORTHO CLINICAL DIAGNOSTICS H (OCDX) stock?
11 analysts have analysed OCDX and the average price target is 21.74 null. This implies a price increase of 23.3% is expected in the next year compared to the current price of 17.63.
Should I buy OCDX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OCDX.
What is the expected growth for OCDX stock?
The Revenue of ORTHO CLINICAL DIAGNOSTICS H (OCDX) is expected to grow by 1.8% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
OCDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OCDX. When comparing the yearly performance of all stocks, OCDX turns out to be only a medium performer in the overall market: it outperformed 50.31% of all stocks.
OCDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OCDX. While OCDX is still in line with the averages on profitability rating, there are concerns on its financial health.
OCDX Financial Highlights
Over the last trailing twelve months OCDX reported a non-GAAP Earnings per Share(EPS) of 0.81. The EPS increased by 99.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -0.02% | ||
| ROA | -0.01% | ||
| ROE | N/A | ||
| Debt/Equity | 4.91 |
OCDX Forecast & Estimates
11 analysts have analysed OCDX and the average price target is 21.74 null. This implies a price increase of 23.3% is expected in the next year compared to the current price of 17.63.
For the next year, analysts expect an EPS growth of 11.82% and a revenue growth 1.8% for OCDX